Skip to main content

Table 2 Effectiveness of DDR deficiencies in predicting ICI efficacy in solid tumors

From: The role of DNA damage repair (DDR) system in response to immune checkpoint inhibitor (ICI) therapy

Clinical endpoint

DDR deficiency

ICI

Cancer type

Proficiency type

Deficiency type

Refs

ORR

HR

Nivolumab+ipilimumab

Prostate cancer

22.6%

50.0%

[13]

DDR positive

Nivolumab+ipilimumab

Prostate cancer

23.1%

36.4%

[13]

DDR positive

ICI

Prostate cancer

20.0%

40.0%

[48]

MMR

Pembrolizumab

Colorectal cancer

0.0%

40.0%

[24]

PFS

MMR

Pembrolizumab

Colorectal cancer

2.2 m

NR

[24]

OS

MMR

Pembrolizumab

Colorectal cancer

5.0 m

NR

[24]

HR

Nivolumab+ipilimumab

Prostate cancer

19.0 m

NR

[13]

  1. Abbreviations: ORR Objective response rate, PFS Progression-free survival, OS Overall survival, NR Not reached